Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced /ˈfɑrmə/), founded in 1958, is a trade group representing the pharmaceutical research and biopharmaceutical companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biopharmaceutical research companies. PhRMA's current CEO is John J. Castellani.
Mission
On its website, PhRMA states its "mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical / biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving in Washington, D.C., the states and the world:[1]
- "Broad patient access to safe and effective medicines through a free market, without price controls,
- "Strong intellectual property incentives, and
- "Transparent, efficient, regulation and a free flow of information to patients."
Leadership
John J. Castellani
John J. Castellani is President and CEO of PhRMA. Castellani has promised that PhRMA will continue to support healthcare reform efforts in the United States and abroad. Specifically, PhRMA will focus on helping to successfully implement and improve the health reform legislation passed in 2010 under President Obama with a particular emphasis on rewarding innovation.[2]Jeffrey Kindler, the chairman of Pfizer and former chairman of PhRMA, when commenting on Castellani's move from the Business Roundtable to PhRMA, said, “John is the gold standard, and I’m extremely pleased that he will lead our team."[3] Mr. Castellani succeeds Billy Tauzin, a former Republican congressman from Louisiana.[3]
Robert Hugin
Robert Hugin is the Chairman of PhRMA's board of directors. Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985. He served in the United States Marine Corps.[4]
Billy Tauzin
Tauzin started as CEO in 2005[5] and continued until he stepped down in 2010.[6]
American Legislative Exchange Council
Jeffery Bond, representing PhRMA, sits on the Private Enterprise Board of the American Legislative Exchange Council (ALEC).[7]
Issues
Medicare part D
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (April 2011) |
Patient Protection and Affordable Care Act
| This section needs expansion. You can help by adding to it. (April 2011) |
Intellectual property
Every year, PhRMA makes substantial efforts with regard to Special 301 Report issued by the Office of the United States Trade Representative on the enforcement of intellectual property laws abroad.[citation needed] PhRMA's recommendations for the Special 301 Report in 2009 were especially critical of the Philippines for "breaking patents" and failing to abide by the Agreement on Trade-Related Aspects of Intellectual Property Rights, commonly known as TRIPS.[8]
Programs for patients
SMARxT Disposal
SMARxT Disposal is a joint program run by the U.S. Fish and Wildlife Service, the American Pharmacists Association, and PhRMA to encourage consumers to properly dispose of unused medicines in order to avoid harm to the environment.[9]
Partnership for Prescription Assistance
The Partnership for Prescription Assistance is a program by PhRMA and its member companies that connects patients in-need with information on low-cost and free prescription medication.[9]
Members
Some prominent members of PhRMA include the following. A full list of members is available at the PhRMA website.[10]
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly and Company
- Genzyme Corporation
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
See also
- Big Pharma: How the World's Biggest Drug Companies Control Illness
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Food and Drug Administration (FDA, USA)
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
- SAFE-BioPharma Association (SAFE)
- International Intellectual Property Alliance (IIPA)
References
- ^ "Mission Statement". PhRMA. Retrieved 6 August 2013.
- ^ whorunsgov.com
- ^ a b Pharmaceutical group shifts tone with new pick for president, by N.C. Alzenman and Dan Eggen, The Washington Post, 14 July 2010
- ^ "Robert Hugin Biography". Pharmaceutical Research and Manufacturers of America. Retrieved 6 April 2013.
- ^ Judy Sarasohn Special Interests: Tauzin to Head Drug Trade Group The Washington Post December 16, 2004; Page A35.
- ^ Julian Pecquet. "PhRMA picks new president" The Hill July 14, 2010. Vol. 17 Issue 81 page 22.
- ^ http://www.alec.org/about-alec/private-enterprise-board/
- ^ Jessica Anne D. Hermosa (4 March 2009). "US lobby wants RP penalized for cheaper drugs law". BusinessWorld.
{{cite news}}:|access-date=requires|url=(help) - ^ a b "Patient Resrouces". Pharmaceutical Research and Manufacturers of America. Retrieved 6 April 2011.
- ^ [1]
External links